Directors of hVIVO plc
Dr Trevor Phillips, Executive Chairman
Dr Trevor Phillips became a Non-Executive Director of hVIVO plc in June 2017 and Executive Chairman in November 2017. Trevor has over thirty years of experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities. He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focused on respiratory diseases. Subsequent to joining Vectura in 2010, Trevor played an integral leadership role in the company’s successful development, including the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016.
Prior to joining Vectura, Trevor held the roles of Chief Executive Officer and Chief Operating Officer at Critical Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty pharmaceutical company, where he was involved in setting up commercial partnerships, product in-licensing and out-licensing, managing drug development, commercial product manufacturing and M&A activity. He led the merger of Critical Therapeutics with Cornerstone BioPharma Holdings. He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc).
Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986. He was awarded an MBA from Henley Management College in 1997.
Graham Edward Yeatman, Chief Financial & Business Officer
Graham joined hVIVO Services Limited (formerly Retroscreen Virology Limited) as Finance Director in May 2011 and became Finance Director of hVIVO plc (formerly Retroscreen Virology Group plc) in April 2012. Graham was promoted to Chief Financial and Business Officer in January 2015.
Graham has significant experience of building businesses for rapid growth and profitability. He is a Chartered Accountant and trained and worked with PricewaterhouseCoopers for thirteen years across its audit, tax, consultancy, business process reengineering and outsourcing divisions. In 2001 he joined buyingTeam Limited (subsequently renamed Proxima) as Finance & Operations Director and was influential in growing the business to become one of the UK’s leading purchasing services providers. In 2006 he joined Neuropharm Group plc as Chief Financial Officer. Graham has a First in Economics and Maths from Bristol University.
Dr Trevor Nicholls, Non-Executive Director
Dr Trevor Nicholls became a non-executive director of the Company on 21 May 2014.
Trevor is a company director having over 30 years of building international businesses in the life science industry, with a strong focus on genomics and proteomics. In particular, he was previously Chairman of Oxford Nanopore Technologies Limited, is currently Chairman of Avacta Group plc and was the Chairman of Activiomics Limited prior to its acquisition by Retroscreen. Trevor is also Chief Executive Officer of CABI, a not-for-profit inter-governmental organisation owned by 46 member countries worldwide. Prior to his current role with CABI, he was Chief Commercial Officer for Affymetrix Inc with accountability for global operations, delivering $330 million revenue with 600 staff across 8 locations worldwide.
His technology knowledge and leadership will be invaluable as Retroscreen expands its bio-analytical activities.
Dr Mark Warne, Non-Executive Director
Mark Warne became a Non‑Executive Director of hVIVO in April 2016 and is Chairman of the Remuneration Committee.
Mark is Chief Executive Officer of DeepMatter Group plc and is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group plc, a leading intellectual property commercialisation company, where he led the Healthcare team. Mark is a Non-Executive Director of IXICO plc and Genomics plc.
He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry.
James F. Winschel, Non-Executive Director
James F. Winschel became a non-executive director of the Company on 1 October 2014 and is Chairman of the Audit Committee.
Jim retired in June 2014 as Executive Vice President at PAREXEL International Corporation (“PAREXEL”), a US publicly-traded healthcare services company (NASDAQ: PRXL) with $1.9 billion in annual service revenue. He previously served as Senior Vice President and Chief Financial Officer of PAREXEL from 2000 to 2013, with responsibility for directing all financial activities, during a period when PAREXEL’s revenue grew by $1.5 billion, backlog increased by $4.5 billion and market capitalisation increased from $225 million to $2.7 billion.
Jim is currently a Director of Cambrex Corporation, a US company offering products, services and technologies to accelerate the development and commercialisation of small molecule therapeutics. Earlier in his career, Jim spent five years at BTM Capital Corporation, a Bank of Tokyo-Mitsubishi Ltd. subsidiary, initially as Executive Vice President and Chief Financial Officer for three years from 1995 before being promoted to President, U.B. Vehicle Leasing, Inc. through 2000. Prior to these roles, he was the Vice President – Finance, Physician Services Division at Caremark International, Inc. for two years from 1993 and spent the previous four years at Whirlpool Financial Corporation (WFC), both as the Vice President & Managing Director, Commercial Financing Division and prior to that as the Vice President and Chief Financial Officer. Jim worked for five years in various roles at General Electric Capital Corporation, in the Transportation and Industrial Financing Division and prior to that at General Electric Company for eleven years.
Jim holds an MBA in Accounting and a BSc in Finance from Syracuse University in the USA.